203 related articles for article (PubMed ID: 26139061)
1. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.
Patrono C
J Am Coll Cardiol; 2015 Jul; 66(1):74-85. PubMed ID: 26139061
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of aspirin as a chemopreventive agent.
Dovizio M; Bruno A; Tacconelli S; Patrignani P
Recent Results Cancer Res; 2013; 191():39-65. PubMed ID: 22893199
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways.
Sankaranarayanan R; Kumar DR; Altinoz MA; Bhat GJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260951
[TBL] [Abstract][Full Text] [Related]
4. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
5. Use and safety of aspirin in the chemoprevention of colorectal cancer.
Singh AK; Trotman BW
J Assoc Acad Minor Phys; 1998; 9(2):40-4. PubMed ID: 9648425
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
9. The role of aspirin in colorectal cancer chemoprevention.
Singh Ranger G
Crit Rev Oncol Hematol; 2016 Aug; 104():87-90. PubMed ID: 27289249
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of aspirin resistance.
Patel D; Moonis M
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):969-75. PubMed ID: 17867925
[TBL] [Abstract][Full Text] [Related]
11. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1.
Lichtenberger LM; Fang D; Bick RJ; Poindexter BJ; Phan T; Bergeron AL; Pradhan S; Dial EJ; Vijayan KV
Cancer Prev Res (Phila); 2017 Feb; 10(2):142-152. PubMed ID: 27998883
[TBL] [Abstract][Full Text] [Related]
12. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
13. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of aspirin resistance.
Floyd CN; Ferro A
Pharmacol Ther; 2014 Jan; 141(1):69-78. PubMed ID: 23993980
[TBL] [Abstract][Full Text] [Related]
15. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Schrör K
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):473-84. PubMed ID: 22122764
[TBL] [Abstract][Full Text] [Related]
17. TXA2 synthesis and COX1-independent platelet reactivity in aspirin-treated patients soon after acute cerebral stroke or transient ischaemic attack.
Valles J; Lago A; Moscardo A; Tembl J; Parkhutik V; Santos MT
Thromb Res; 2013 Aug; 132(2):211-6. PubMed ID: 23830213
[TBL] [Abstract][Full Text] [Related]
18. Role of platelets in inflammation and cancer: novel therapeutic strategies.
Dovizio M; Alberti S; Guillem-Llobat P; Patrignani P
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):118-27. PubMed ID: 24118902
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors.
Ranger GS
Anticancer Res; 2014 Nov; 34(11):6277-82. PubMed ID: 25368225
[TBL] [Abstract][Full Text] [Related]
20. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
